Headlines about Johnson & Johnson (NYSE:JNJ) have been trending positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Johnson & Johnson earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.4578828019409 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern’s rankings:
- Vetr Upgrades Johnson & Johnson (JNJ) to Buy (americanbankingnews.com)
- Attractively Valued Dividend Kings – Seeking Alpha (seekingalpha.com)
- Johnson & Johnson (JNJ) Cut to Hold at Vetr (americanbankingnews.com)
- Johnson & Johnson (JNJ) Updates FY17 Earnings Guidance (americanbankingnews.com)
- CORRECTION – National Association of Corporate Directors (markets.financialcontent.com)
Shares of Johnson & Johnson (NYSE JNJ) traded down $0.94 during mid-day trading on Monday, hitting $140.12. 4,665,500 shares of the stock were exchanged, compared to its average volume of 5,897,919. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $144.35. The company has a market capitalization of $376,440.00, a price-to-earnings ratio of 24.33, a PEG ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a dividend of $0.84 per share. The ex-dividend date was Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.40%. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.
Several brokerages have issued reports on JNJ. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a report on Monday, September 18th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Citigroup lifted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Jefferies Group raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $145.00 to $157.00 in a report on Wednesday, October 11th. Finally, Argus lifted their target price on shares of Johnson & Johnson from $145.00 to $165.00 and gave the stock a “positive” rating in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $145.47.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.